Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PRAX

SELL

Praxis Precision Medicines, Inc. · Healthcare · United States · $9.1B · Avg Vol: $166M/d

29
StockRank
Get insider-trade alerts
Q
32
V
25
M
63
P/E (TTM)
—
ROE
-35.3%
D/E
0.0x
Dividend %
—
Dir. Trades · 180d
−$3.6M →
Buybacks · 180d
None →

COMPANY DESCRIPTION

Praxis Precision Medicines, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system (CNS) disorders. Its drug pipeline targets conditions such as epilepsy, movement disorders, and depression by addressing neuronal excitation-inhibition imbalance. The company distinguishes itself through a precision medicine approach, aiming to provide targeted treatments for patients with high unmet medical needs.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGRTTM2026E2027EFwd CAGR
Revenue02.4M8.6M0249.5%—2.3M342.4M242.1%
EPS-8.22-5.89-10.21-13.48—-12.96-15.32-9.66—
Shares27.9M27.9M19.4M25.2M-9.6%27.9M———
Debt3.5M2.5M1.4M0.1M-68.4%1.4M———
Equity76.1M69.7M445.4M878.1M126.0%————
Op CF-185.0M-111.1M-131.8M-249.1M—-282.2M———
Inv CF96.9M39.0M-248.5M-311.1M—————
Fin CF10.5M91.9M514.3M702.2M—————
Loading 1Y...
PRICE (1Y)+31.2%
248274299325351Jun 11Jul 6Jul 24
SMA 50SMA 200
Close
$325.30
RSI (14)
54.9
52W High
$366.52
From 52W High
0.9%

SCORE BREAKDOWN

Quality
32
ROIC
-37.1%20.3
ROE
-35.3%24.1
GP/Assets
-30.3%3.2
Op. Margin
0.0%41.3
FCF/Assets
-18.8%20.0
Piotroski
321.7
Int. Cover
—N/A
D/E Ratio
0.00x93.3
Current Ratio
15.88x93.0
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-21.6x25.0
P/FCF
—N/A
P/B
6.0x22.3
P/S
—N/A
Div Yield
—N/A
Momentum
63
52W High %
89%84.6
RS 6M
-1%73.1
SMA 50/200
1.12x83.8
EPS Rev 4W
+1.6%86.3
EPS Rev 12W
-12.5%11.8
EPS Improve
+25%38.3
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$9.1B
P/E (Forward)
-31.5x
Gross Margin
0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PRAX are excluded.

TickerCompanyMkt CapStockRankSignal
PRAXPraxis Precision Medicines, Inc.(you)$9.1B29SELL
CRNXCrinetics Pharmaceuticals, Inc.$8.9B30SELL
NUVLNuvalent, Inc.$9.8B30SELL
SYRESpyre Therapeutics, Inc.$8.9B32SELL
KYMRKymera Therapeutics, Inc.$9.1B25SELL
RYTMRhythm Pharmaceuticals, Inc.$7.0B30SELL
PCVXVaxcyte, Inc.$7.9B27SELL
ERASErasca, Inc.$6.6B31SELL
IBRXImmunityBio, Inc.$7.4B26SELL
CYTKCytokinetics, Incorporated$11.0B26SELL

Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%

Praxis Precision Medicines, Inc. (PRAX) — Stock Score Summary

Praxis Precision Medicines, Inc. (PRAX) has a MoatMap StockRank of 29/100 based on Quality (32/100), Value (25/100), and Momentum (63/100) factor scores. The current signal is SELL.

Praxis Precision Medicines, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system (CNS) disorders. Its drug pipeline targets conditions such as epilepsy, movement disorders, and depression by addressing neuronal excitation-inhibition imbalance. The company distinguishes itself through a precision medicine approach, aiming to provide targeted treatments for patients with high unmet medical needs.

Key Financial Metrics

Price$325.30
Market Cap$9.1B
P/E (Forward)-31.53
Price/Book6.02
Return on Equity-35.3%
Return on Invested Capital-37.1%
Debt/Equity0.00x
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-176M

Praxis Precision Medicines, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Praxis Precision Medicines, Inc.’s (PRAX) StockRank?
MoatMap’s StockRank for Praxis Precision Medicines, Inc. (PRAX) is 29/100, with a Sell signal. It is a composite of Quality (32), Value (25), and Momentum (63) factor ranks across MoatMap’s 20,000+ stock universe.
Does Praxis Precision Medicines, Inc. have an economic moat?
Praxis Precision Medicines, Inc. (PRAX) has a Quality factor score of 32/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Praxis Precision Medicines, Inc. a buy, hold, or sell?
MoatMap’s current signal for Praxis Precision Medicines, Inc. (PRAX) is Sell, based on a StockRank of 29/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Praxis Precision Medicines, Inc. in?
Praxis Precision Medicines, Inc. (PRAX) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksPRAX deep dive reportAI ChampionsHow we score stocksSense-check another stock